MaxCyteMXCT -2.41%59 PS Ratio is 4.02 as of Jun. 30, 2026, which is 64% below its 10-year median of 11.30. GuruFocus rates MXCT with a GF Score™ of 59/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 804 Medical Devices & Instruments companies, MaxCyte ranks worse than 64.55% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, MaxCyte's share price is $1.215.
MaxCyte's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.30. Hence, MaxCyte's PS Ratio for today is 4.02.
The historical rank and industry rank for MaxCyte's PS Ratio or its related term are showing as below:
MXCT'
s PS Ratio Range Over the Past 10 Years
Min: 2.21 Med: 11.3 Max: 43
Current: 4.02
During the past 13 years, MaxCyte's highest PS Ratio was 43.00. The lowest was 2.21. And the median was 11.30.
MXCT's PS Ratio is ranked worse than 64.55% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs MXCT: 4.02
MaxCyte's Revenue per Sharefor the
three
months ended in Mar. 2026 was $0.09.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.30.
Warning Sign:
MaxCyte Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of MaxCyte was -15.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -10.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -3.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 3.20% per year.
During the past 13 years, MaxCyte's highest 3-Year average Revenue per Share Growth Rate was 32.60% per year. The lowest was -10.70% per year. And the median was 4.70% per year.
Back to Basics: PS Ratio
MaxCyte (NAS:MXCT) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
MaxCyte PS Ratio Related Terms
MaxCyte PS Ratio Historical Data
* Premium members only.
The historical data trend for MaxCyte's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MaxCyte's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's PS Ratio distribution charts can be found below:
* The bar in red indicates where MaxCyte's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
MaxCyte's Share Price of today is $1.215. MaxCyte's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.30.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
MaxCyte (MXCT) has a PS Ratio of 4.02 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on MaxCyte and its competitors. This is 64% below median its historical median of 11.30. Over the past decade, MaxCyte's PS Ratio has ranged from 2.21 to 43.00. According to the industry distribution chart, MaxCyte ranks #519 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 64.6%.
Is MaxCyte's PS Ratio too high?
MaxCyte's current PS Ratio of 4.02 is 64% below median its 10-year median of 11.30. Over the past 10 years, this metric has ranged from a low of 2.21 to a high of 43.00. The Medical Devices & Instruments industry median PS Ratio is 2.94. MaxCyte's value of 4.02 is 36.7% above this industry median. Based on the distribution chart, MaxCyte ranks #519 out of 804 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, MaxCyte has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's PS Ratio compare to RCEL and HYPR?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #519 out of 804 companies for PS Ratio. This places MaxCyte in the lower half of its industry. The industry median PS Ratio is 2.94. MaxCyte's value of 4.02 is 36.7% above this benchmark. Historically, MaxCyte's own PS Ratio has ranged from 2.21 to 43.00 over the past decade. While the company's 10-year median is 11.30 vs. the industry median of 2.94, MaxCyte has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MaxCyte's current PS Ratio of 4.02 is 36.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on MaxCyte and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MaxCyte's current PS Ratio is 4.02, which is 64% below median its own 10-year median of 11.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.22 — trading 52.7% below its estimated fair value. The current PS Ratio is 4.02, which is 64% below median its 10-year median of 11.30 and 36.7% above the Medical Devices & Instruments industry median of 2.94. MaxCyte's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For MaxCyte (MXCT), the current PS Ratio is 4.02 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.22 is trading 52.7% below its estimated GF Value™ of $2.57.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
PS Ratio: 4.02 (64% below median its 10-year median of 11.30)
GF Value™: $2.57 vs. price of $1.22 (52.7% below fair value)
Industry Position: 36.7% above the Medical Devices & Instruments median (#519 of 804)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
59GF Score
Get the complete analysis for MXCT
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
